Call Us : 1.224.938.9523 meetings@worldeventsforum.com

Program

22nd ANNUAL MILD COGNITIVE IMPAIRMENT SYMPOSIUM 
Friday, April 19, 2024 (9:30 am – 4:45 pm US Eastern Time)

THE ANNUAL ALZHEIMER’S PUBLIC EDUCATIONAL FORUM
Friday, April 26, 2024 (1:00 pm – 4:00 pm US Eastern Time)

Schedule

MCI Symposium Program 

Friday, April 19, 2024

All times in US Eastern Time.

9:30 am
Introductory Notes on the 22nd Annual MCI Symposium
9:30
SESSION 1: Role of Plasma Biomarkers of AD Pathology in Diagnosis of Patients with Cognitive Complaints
9:30
Session Overview
9:40
Keynote: Cognitive changes associated with Abeta and tau pathology in normal aging
10:05
Q&A
10:15
Longitudinal changes in plasma biomarkers in ATRI studies, including the A4 Study
10:30
Q&A
10:35
Plasma brain-derived tau as a sensitive biomarker of neurodegeneration
10:50
Q&A
10:55
Plasma biomarkers in the MCI population
11:10
Q&A
11:15
Relations of plasma biomarkers to imaging biomarkers in ethnically diverse individuals
11:30
Q&A
11:35
Plasma biomarkers in Mild Behavioral Impairment
11:50
Q&A
11:55
Discussion
12:15
Break
12:45
SESSION 2: Implementation of a Treatment Program using Anti-Amyloid Monoclonal Antibodies
12:45
Session Overview
1:10
Keynote: Challenges in initiating anti-amyloid monoclonal antibody treatment
1:20
Q&A
1:35
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease
1:40
Q&A
1:55
Distinguishing subjective memory complaints from MCI and mild dementia in a multi-ethnic population
2:00
Q&A
2:15
Plasma biomarker strategy for selecting patients for anti-amyloid immunotherapies and determining treatment response
2:20
Q&A
2:30
Break
2:30
Case Presentations: Determination of Candidacy for Anti Amyloid Treatment, AD, Risk for ARIA and Monitoring Treatment Progress
2:45
2:50
Q&A
3:05
3:10
Q&A
3:25
3:30
Q&A
3:45
3:50
Q&A
4:05
4:10
Q&A
4:30
Group Discussion
4:45
Conclusion
9:30 am
Ranjan Duara, MD, MRCP, FAAN, Mt Sinai Medical Center/Wien Center for Alzheimer's Disease and Memory Disorders
9:30
Chair
9:30
Chair
9:40
Reisa Sperling, MD, Brigham and Women’s Hospital, USA
10:05
Q&A
10:15
Robert Rissman, PhD, University of Southern California, USA
10:30
Q&A
10:35
Thomas Karikari, PhD, University of Pittsburgh, USA
10:50
Q&A
10:55
Nicholas Ashton, PhD, University of Gothenburg
11:10
Q&A
11:15
Breton Asken, PhD, University of Florida, USA
11:30
Q&A
11:35
Firoza Lussier, PhD, McGill University, Canada
11:50
Q&A
11:55
Discussion
12:15
Break
12:45
Ronald Petersen, MD, PhD, Mayo Clinic, Rochester
12:45
Chair
1:10
Suzanne Schindler, MD, PhD, Washington University in St Louis, USA
1:20
Q&A
1:35
Madhav Thambisetty, MD, PhD, NIA, NIH, USA
1:40
Q&A
1:55
Rosie Curiel, PsyD, University of Miami, USA
2:00
Q&A
2:15
Niklas Mattsson-Carlgren, MD, PhD, Lund University, Sweden
2:20
Q&A
2:30
Break
2:30
Case Presentations: Determination of Candidacy for Anti Amyloid Treatment, AD, Risk for ARIA and Monitoring Treatment Progress
2:45
Stephen Salloway, MD, MS, Brown University, USA
2:50
Q&A
3:05
Gil Rabinovici, MD, PhD, UCSF, USA
3:10
Q&A
3:25
Vijay Ramanan, MD, PhD, Mayo Clinic, USA
3:30
Q&A
3:45
Larry Honig, MD, PhD, Columbia University, USA
3:50
Q&A
4:05
John Dickson, MD, PhD, Massachusetts General Hospital
4:10
Q&A
4:30
Group Discussion
4:45
Ranjan Duara, MD, FAAN, Mount Sinai Medical Center Miami, USA

SYMPOSIUM CONVENER

Ranjan Duara, MD, MRCP, FAAN

Dr. Ranjan Duara is the Medical Director of the Wien Center for Alzheimer’s Disease and Memory Disorders at Mount Sinai Medical Center and holds the Denis C. Cole Family Chair in Alzheimer’s Disease Research. In addition, Dr. Duara serves the Associate Director and leader of the Clinical Core of the 1Florida Alzheimer’s Disease Research Center, a research collaboration between four university medical centers and Mount Sinai Medical Center in Florida. Dr. Duara is a Courtesy Professor of Neurology at the University of Florida College of Medicine, Gainesville, Florida, and the Herbert Wertheim College of Medicine, Florida International University, Miami, Florida. He serves as the Principal Investigator of the State of Florida Dementia Brain Bank Program.

Dr. Duara is a clinical neurologist with a special interest in the use of brain imaging for the diagnosis and treatment of Alzheimer’s disease and other causes of Adult Cognitive Disorders. Through his research in this area, he has helped to enhance what is known about the biology of Alzheimer’s disease.

He completed his undergraduate medical education at Christian Medical College, Vellore, South India, completed two years of neurology residency with Dr. Noshir Wadia at Grant Medical College in Bombay, India, followed by residencies in internal medicine and neurology in the United Kingdom, and in neurology at Thomas Jefferson University Hospital in Philadelphia. He then completed a four-year fellowship in neuroscience and neuroimaging of aging, with Dr Stanley Rapaport at the National Institute on Aging (National Institutes of Health, Bethesda, MD).

Dr. Duara’s research has focused primarily on early diagnosis of Alzheimer’s disease and other dementias, neuroimaging, genetic epidemiology, and the methodology for staging the transition from normal cognitive aging to dementia. He has contributed to more than 250 articles in peer-reviewed scientific journals and has been an investigator in observational studies on aging, as well as clinical trials of novel agents for the treatment of Alzheimer’s Disease. Dr. Duara is also the chair and organizer of the Mild Cognitive Impairment Symposium, which is held annually in Miami Beach.

CHAIRS AND PRESENTERS

Nicholas Ashton, PhD

Dr. Nicholas Ashton is an associate professor of neurochemistry at the Department of Psychiatry and Neurochemistry at the University Gothenburg. He also holds a senior researcher position at the department of Old Age Psychiatry, King’s College London. He received his PhD in 2017 from King’s College London in the group of Professor Simon Lovestone.

Dr. Ashton has a >10 years of experience in biofluid analysis and assay development for Alzheimer’s disease which ranges from discovery mass spectrometry methods to ultra-sensitive immunoassays. Recently this work has produced ultra-sensitive single molecular array (Simoa) assays for phosphorylated tau in blood, which are now widely used in research settings, therapeutics trials and being validated for clinical use.

He has published >200 original research articles in field of fluid biomarkers and in 2021, Dr. Ashton was awarded the Queen Silvia’s Prize to a Young Alzheimer Researcher for his contribution dementia research and the Viola prize for mentorship.

Breton Asken, PhD

Dr. Breton Asken is an Assistant Professor in the Department of Clinical and Health Psychology at the University of Florida. He is also a Fixel Scholar in the Normal Fixel Institute for Neurological Disorders. Dr. Asken completed bachelors degrees at the University of North Carolina at Chapel Hill (Exercise & Sport Science – Athletic Training, Psychology) where he also worked as a research assistant in the Matthew Gfeller Sport-Related Traumatic Brain Injury Research Center and completed his Athletic Training Certification (ATC). He then earned his doctorate in Clinical Psychology (Neuropsychology track) from the University of Florida and completed his clinical internship in neuropsychology at Brown University. Prior to joining faculty at UF, Dr. Asken completed a postdoctoral fellowship in neuropsychology at the UCSF Memory and Aging Center.

As a clinical neuropsychologist, Dr. Asken evaluates patients with a range of cognitive and behavioral conditions at the Fixel Institute for Neurological Diseases and the UF Memory Disorders Clinic. He specializes in neuropsychological evaluation of patients with suspected neurodegenerative diseases like Alzheimer’s disease, as well as less common conditions including traumatic encephalopathy syndrome, primary progressive aphasia, behavioral variant frontotemporal dementia, Lewy body related disorders, corticobasal syndrome, and progressive supranuclear palsy. Dr. Asken’s clinic works closely with colleagues in behavioral neurology to support multidisciplinary patient care.

As a researcher, Dr. Asken’s work broadly focuses on how lifetime head trauma exposure relates to clinical and neuropathological variability among patients with Alzheimer’s disease and related causes of dementia, including chronic traumatic encephalopathy (CTE). This work involves using a combination of neuropsychological testing, fluid-based biomarkers (blood, CSF), neuroimaging, and neuropathology to address the links between head trauma and dementia. Dr. Asken is especially interested in how biomarkers and cognitive testing can help improve diagnosis, prognosis, and treatment of mixed etiology dementia, or progressive cognitive/behavioral decline in later life due to multiple co-existing neurodegenerative diseases. Prior work focused on fluid biomarkers and recovery outcomes associated with sport-related concussion, and this experience relates directly to his current interests in the later-life neurological effects of head trauma exposure, especially among former athletes. Dr. Asken has active collaborations with investigators across UF as well as multiple institutions around the country.

Rosie Curiel, PsyD

Dr. Rosie Curiel is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine and faculty member of the Center on Aging. As a geriatric neuropsychologist, she has an expertise in the assessment of neurodegenerative conditions among elders. Dr. Curiel is Principal Investigator of a study entitled: Precision-based Computerized Assessment for the Detection of MCI in Older Adults, and is an active Co-investigator on various state and federally funded longitudinal Alzheimer’s disease studies including the 1Florida Alzheimer’s Disease Research Center.

Her program of research focuses on the development of novel and cross-culturally applicable cognitive assessment paradigms. She and her team have generated promising pilot data that these novel cognitive outcome measures are sensitive enough to detect subtle deficits specific to preclinical Alzheimer’s disease, and are highly associated with biological markers of early AD pathology. Her program of research focuses on technologically enhancing these innovative cognitive paradigms into user-friendly clinical outcome measures with the goal of advancing cognitive assessment efforts in clinical trials targeting preclinical AD.

John Dickson, MD, PhD

Dr. John Dickson is a neurologist specializing in Alzheimer disease and related disorders at Massachusetts General Hospital. He has been involved in developing the Alzheimer Therapeutics Program (ATP) for the evaluation and management of patients receiving anti-amyloid therapies in the Mass General Brigham healthcare system. In addition to his clinical work, Dr. Dickson’s research focuses on understanding Alzheimer disease pathophysiology.

Lawrence Honig, MD, PhD

Dr. Lawrence Honig is a Professor of Neurology at Columbia University Irving Medical Center, at the Vagelos College of Physicians and Surgeons (New York, NY), in the Department of Neurology (Division of Aging and Dementia), the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, the Gertrude H. Sergievsky Center, and at New York Presbyterian Hospital. He directs the New York State Center of Excellence for Alzheimer’s Disease, co-directs the Lewy Body Disease Association Research Center of Excellence, and the Progressive Supranuclear Palsy Center of Care, and is Deputy Director of the Alzheimer’s Disease Research Center.

Dr. Honig obtained his MD medical degree from the University of Miami (Miami, Florida), and his PhD from the University of California at Berkeley (Berkeley, California). He underwent postgraduate internship in Medicine and residency in Neurology training at Stanford University Medical Center (California). He served on the faculty of the Neurology departments at Stanford University Medical Center, and then at the University of Texas Southwestern Medical Center in Dallas, prior to his arrival at Columbia University, where he has been on the faculty since the year 2000. He is a neuroscientist and board-certified clinical neurologist, with UCNS subspecialty certifications in Behavioral Neurology and Neuropsychiatry, and Geriatric Neurology. His clinical specialization focusses on Alzheimer’s Disease, Lewy Body Dementia, Frontotemporal Dementias, Progressive Supranuclear Palsy, Creutzfeldt-Jakob disease, immune-mediated encephalitides, and other disorders of nervous system aging and degeneration. He is a principal investigator on both observational and clinical drug trials for neurodegenerative conditions including Alzheimer Disease, Frontotemporal Degeneration, Lewy Body Disease, and Progressive Supranuclear Palsy.

Thomas Karikari, PhD

Dr. Thomas K. Karikari is Assistant Professor at University of Pittsburgh and scientist at the Clinical Neurochemistry Laboratory at the University of Gothenburg in Sweden. His main research interest is to further understand molecular and biochemical basis of pathological changes in the Alzheimer brain and apply this knowledge to develop new biofluid-based diagnostic tools for clinical use. To this end, he uses advanced and highly sensitive clinical chemistry techniques that allow quantification of tiny differences in biomarker concentrations in blood and cerebrospinal fluid. Thomas has received major scientific awards for his discovery and development of blood p-tau biomarkers, including from the Swedish Alzheimer Foundation and the Nordic Federation for Clinical Chemistry.

He completed his undergraduate studies in biochemistry at the Kwame Nkrumah University of Science and Technology in Kumasi, Ghana, followed by a Master’s degree in pharmaceutical biotechnology in Leicester, England. Thomas received his PhD in 2018 from Warwick university in Coventry, England, where he developed and applied biochemical, molecular and cell biology approaches to investigate functional and structural consequences of genetic mutations in the MAPT gene associated with different tauopathies.

At the end of his PhD, Thomas was a visiting scholar at Harvard Medical School where he investigated kinetic cytotoxicity of aggregated tau. He then moved to Gothenburg, Sweden, as a postdoctoral fellow in clinical chemistry under the mentorship of Professors Kaj Blennow and Henrik Zetterberg.

Firoza Lussier, MS

Firoza Lussier is currently investigating possible associations between behavioral symptoms and Alzheimer’s disease pathophysiology in both healthy and clinical populations as a member of the investigation team at McGill University Research Centre for Studies in Aging (MCSA). She is completing her PhD in neuroscience at McGill University.

Niklas Mattsson-Carlgren, MD, PhD

Dr. Niklas Mattsson-Carlgren is a Senior lecturer at Lund University, Sweden, where he serves in the Department of Clinical Studies, Clinical Memory Research, directing his research primarily toward Alzheimer’s disease (AD) and various neurodegenerative conditions. In addition to this focal point, he explores acute brain injuries, specifically those following cardiac arrest, and investigates the neurochemistry of different aspects of the brain, such as pain regulation and sleep patterns. Employing a comprehensive approach, Dr. Mattsson-Carlgren relies on biochemical measurements, neuroimaging, and cognitive testing to examine disease processes in vivo within human subjects. The scope of his research spans from molecular mechanisms to clinical characteristics, covering the entire continuum from preclinical disease stages to advanced dementia. His main objectives include enhancing diagnostic and prognostic methods in clinical practice, refining the design of clinical trials to facilitate the development of novel therapies, and gaining a novel understanding of disease mechanisms.

Ronald Petersen, MD, PhD

Dr. Ronald Petersen is a national leader in the field of Alzheimer’s research. He is the director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study on Aging. He has authored over 550 peer-reviewed articles and edited five books on memory disorders, aging, and Alzheimer’s disease. Dr. Petersen received his Ph.D. in Experimental Psychology from the University of Minnesota and graduated from Mayo Medical School in 1980. He joined the staff of the Mayo Clinic in 1986. He became the Cora Kanow Professor of Alzheimer’s Disease Research in 2000, and was named the Mayo Clinic Distinguished Investigator in 2011.

Dr. Ronald Petersen is one of the recipients of the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s, and Related Disorders of the American Academy of Neurology. He also received the inaugural Ronald and Nancy Reagan Research Institute Award in 2004 from the Alzheimer’s Association and the inaugural Leon Thal Prize of the Lou Ruvo Brain Institute in 2007. In 2012, he received the Khachaturian award of the Alzheimer’s Association and the Henry Wisniewski Lifetime Achievement Award in 2013.

In 2011, he was appointed by the Secretary of Health and Human Services to serve as the chair of the Advisory Committee on Research, Care, and Services for the National Alzheimer’s Project Act and was appointed to the World Dementia Council in 2014 by UK Prime Minister David Cameron.

Gil Rabinovici, MD, PhD

Dr. Gil Rabinovici holds the Edward Fein and Pearl Landrith Distinguished Professorship in Memory & Aging in the UCSF Department of Neurology. He received his BS degree from Stanford University and MD from Northwestern University Medical School. He completed neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the UCSF Memory and Aging Center (MAC), where he cares for patients with cognitive disorders.

Dr. Rabinovici’s research investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and study the biology of neurodegenerative diseases, with the goal of accelerating drug development. He is the director of the NIH-funded UCSF Alzheimer’s Disease Research Center, study chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies (~25,000 total participants), as well as co-PI on the emerging Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), co-PI and PET Core lead of the Longitudinal Evaluation of Alzheimer’s Disease Study (LEADS) and PI on several additional national and local clinical, imaging and translational studies focused on Alzheimer’s disease and related disorders. His work is supported by the NIH, Alzheimer’s Association, American College of Radiology, Rainwater Charitable Foundation and industry partners. He has authored over 290 peer-reviewed publications, and the impact of his work is ranked in the top 1% in the field of Neuroscience.

Dr. Rabinovici’s contributions have been recognized with numerous awards, including the 2022 Kuhl-Lassen Award from the Society for Nuclear Medicine and Molecular Imaging, 2015 Christopher Clark Award in Amyloid Imaging, the 2012 American Academy of Neurology Research Award in Geriatric Neurology and the 2010 de Leon Prize from the Alzheimer’s Association.

Vijay Ramanan, MD, PhD

Dr. Vijay Ramanan is a Neurologist with subspecialty interest in Cognitive/Behavioral Neurology. He collaborates with various teams at Mayo Clinic, including the Study of Aging, Alzheimer’s Disease Research Center, the Aging and Dementia Imaging Research Laboratory, and the Division of Behavioral Neurology clinical practice.

In his primary research focus, Dr. Ramanan explores the intricate genetic and gene-environment interactions influencing clinical heterogeneity within Alzheimer’s disease (AD), Lewy body dementia (LBD), and related neurodegenerative diseases. His work integrates cross-sectional and longitudinal multi-omics, neuroimaging, fluid biomarkers, and clinical and epidemiologic data for groundbreaking discoveries.

Dr. Ramanan delves into three key areas within his areas of research:

In the area of resistance to pathology, he investigates how genetic variation impacts an individual’s susceptibility to neurodegenerative pathologies by integrating genomic data with imaging or fluid measures.

Moving on to resilience against pathology, Dr. Ramanan explores the differential coping mechanisms individuals exhibit in the presence of pathology, such as the maintenance or loss of clinical functioning in response to elevated brain amyloid burden. Identifying and harnessing underlying genetic pathways may pave the way for innovative treatment approaches.

In the realm of clinical heterogeneity, additional efforts center on unraveling genetic and gene-by-environment interactions contributing to sex differences, diverse clinical syndromes, and varying responses to symptomatic medications used for AD and related diseases.

Dr. Ramanan’s research aims to enhance risk prediction, facilitate personalized counseling and management approaches, and provide novel targets for drug therapies in the context of AD, LBD, and related neurodegenerative diseases.

His notable professional achievements include obtaining Behavioral Neurology and Neuropsychiatry Certification from the United Council for Neurologic Subspecialties in 2020, active participation in the Institute on Methods and Protocols for Advancement of Clinical Trials Program in Alzheimer’s and Related Diseases in 2020, receiving the Well-Being Award from Mayo Clinic School of Graduate Medical Education in 2020, serving as an Associate Editor for the Journal of Alzheimer’s Disease since 2019, active participation in the Member Engagement Committee of the American Academy of Neurology since 2019, and being honored with the Mayo Brothers Distinguished Fellowship Award at Mayo Clinic in 2018.

Robert Rissman, PhD

Dr. Robert Rissman is a Professor of Physiology and Neuroscience and the W.M. Keck Endowed Professor in Medicine at University of Southern California. He is the founding Director of the Neuroscience Translational Research Division and the ATRI Biomarker Laboratory and Biorepository. He is the Alzheimer’s Clinical Trials Consortium (ACTC) Biorepository Unit Lead.

The ATRI facility is comprised by a wet laboratory and a large biorepository of -80 freezers to store specimens from clinical trials and longitudinal cohort studies. Using single analyte and multiplex bioassays, the goal of the lab is to identify biomarkers for preclinical AD and better understand how treatment parameters may impact these biomarkers. Concurrently with work at ATRI, Dr. Rissman is a PI at the VA San Diego, Professor of Neurosciences at UC San Diego and leads the ADCS Biomarker Core and ADRC Neuropathology Core.

The goal of Dr. Rissman’s basic science research is on novel biomarker discovery in Alzheimer’s Disease (AD) and preclinical studies in experimental. A major focus of his lab in AD biomarkers is on the utility and mechanistic underpinnings of neuronal exosomes and his group has published manuscripts demonstrating the ability of tau and abeta in neuronal exosomes to predict conversion from MCI to AD. The lab also investigates the contribution of stress and changes in stress signaling intermediates in Alzheimer’s disease neuropathology. Using transgenic mice and in vivo pharmacology, experiments are focused on identifying the role of corticotropin-releasing factor (CRF) receptors in beta-amyloid deposition, tau phosphorylation and behavioral and synaptic changes.

Stephen Salloway, MD, MS

Dr. Stephen Salloway is the founding Director of the Memory and Aging Program at Butler Hospital in Providence, Rhode Island. He is the Martin M. Zucker Professor of Psychiatry and Human Behavior and Professor of Neurology at the Warren Alpert Medical School of Brown University. He received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University.

His research focuses on biomarker and drug development for prevention and early treatment of Alzheimer’s disease (AD). During his time at Brown, the Butler Hospital Memory and Aging Program (MAP) has become an internationally recognized center for clinical research in Alzheimer’s disease. The MAP has helped pioneer the use of PET ligands for amyloid and tau to study the evolution of AD pathophysiology in autosomal dominant and sporadic AD. The program has had a lead role in testing targeted treatments, such as BACE inhibitors and monoclonal antibodies, alone and in combination, to lower amyloid plaques and neurofibrillary tangles, as well as novel approaches, such as deep brain stimulation, to slow the progression of AD. The MAP is developing new strategies using genetic testing and brain imaging to recruit cognitively normal elderly at increased risk for AD for prevention studies.

Dr. Salloway has published more than 370 scientific articles and abstracts and has edited 3 books. These include lead authorship on pivotal trials in the New England Journal of Medicine, the Lancet, Nature, and JAMA Neurology. Dr. Salloway is a past president of the American Neuropsychiatric Association, a fellow of the American Academy of Neurology, and a member of the American Neurological Association. He serves on the Steering Committees for landmark NIH studies such as the Alzheimer’s Disease Neuroimaging Initiative, the Dominantly Inherited Alzheimer’s Network, and the Alzheimer’s Disease Clinical Trial Consortium. He is a scientific reviewer for the National Institutes of Health and for more than 30 journals, universities, and research foundations. Dr. Salloway lectures widely on prevention and early intervention for Alzheimer’s disease.

Suzanne Schindler, MD, PhD

Dr. Suzanne Schindler is a clinical neurologist and neuroscientist focused on improving the diagnosis and treatment of Alzheimer disease. She completed the MD/PhD program at Washington University, where she studied the basic biology of apolipoprotein E (apoE) metabolism in the laboratory of Dr. David Holtzman. Dr. Schindler then trained in clinical neurology at Washington University and completed a fellowship in dementia. Currently Dr. Schindler sees patients with memory concerns, coordinates lumbar punctures for patients seen in the memory clinic, and attends on the neurology consult service. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center. She received a large R01 to evaluate the relationship between plasma biomarkers and symptomatic Alzheimer disease and works closely with Dr. Randall Bateman, who has developed multiple novel fluid biomarker assays. She is very interested in translating research findings into clinical practice. Further, she has a particular focus on understanding and reducing disparities in healthcare.

Reisa Sperling, MD

Dr. Reisa Sperling Dr. Reisa Sperling is a neurologist, specializing in dementia and imaging research. She is a Professor in Neurology at Harvard Medical School. She is also the Director of the Center for Alzheimer Research and Treatment at Brigham and Womenís Hospital, and the Director of the Neuroimaging Core and the Outreach Core of the Massachusetts Alzheimerís Disease Research Center at Massachusetts General Hospital.

Dr. Sperling’s research is focused on the early diagnosis and treatment of Alzheimer’s disease. Her recent work involves the use of functional MRI and PET amyloid imaging to study alterations in brain function in aging and early Alzheimer’s disease. She is the Principal Investigator on multiple NIH and Foundation grants utilizing multi-modality imaging techniques to probe the neural correlates of memory changes in cognitive aging and early AD. She is the PI of the Harvard Aging Brain Study, funded by a NIA Program Project grant. Dr. Sperling oversees a number of clinical trials of potential disease-modifying therapeutics in early Alzheimerís disease, and serves on the Steering Committees for the Alzheimer’s Disease Neuroimaging Initiative and the Dominantly Inherited Alzheimer Network. She has published over 120 peer-reviewed research articles on memory, aging, and early AD.

Dr. Sperling led the National Institute on Aging-Alzheimer’s Association working group to develop guidelines for the study of Preclinical Alzheimer’s disease. She serves as the Project Leader for the ADCS Anti-Amyloid Treatment in Asymptomatic AD (A4 trial), a 3 year secondary prevention trial in 1000 clinically normal older individuals with biomarker evidence of early AD pathology.

Many of Dr. Sperling’s publications may be found at www.ncbi.nlm.nih.gov/

Madhav Thambisetty, MD, PhD

Dr. Madhav Thambisetty  is a Board-certified neurologist with sub-specialty training in cognitive/behavioral neurology and sleep disorders. He completed both residency and fellowship training in the Department of Neurology at Emory University School of Medicine in Atlanta. Prior to training in Neurology, he was awarded a PhD (DPhil) in Clinical Pharmacology from the University of Oxford where he pursued doctoral studies on a Felix scholarship. His PhD thesis examined the role of synaptic remodeling in the actions of anti-depressant treatments. In 2004, he was awarded a research fellowship by the Alzheimer’s Society of the United Kingdom to pursue research into ‘Blood biomarkers of Alzheimer’s Disease’ at the Institute of Psychiatry, King’s College, London. He was elected to the Emanoel Lee medical research fellowship at St. Cross College, Oxford in 2004. In 2016, he was awarded the Norman Geschwind prize in Behavioral Neurology by the American Academy of Neurology (AAN). He is currently also an Adjunct Professor of Neurology at the Johns Hopkins University School of Medicine.

Public Educational Forum Program

Sunday, April 26, 2024

1:00 PM US Eastern Time.

The Countdown Begins!

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

We look forward to welcoming you to our 2024 event!